Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner’s National Priority Voucher Pilot Program
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.…
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
October 15, 2025 17:15 ET | Source: Annovis Bio Inc. MALVERN, Pa.,…
XORTX Completes USD $114,500 Private Placement
August 08, 2025 19:54 ET | Source: XORTX Therapeutics Inc. NOT FOR…
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus
July 04, 2025 15:10 ET | Source: Spectral Medical Inc. TORONTO, July…
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
June 18, 2025 16:30 ET | Source: Cellectar Biosciences, Inc. FLORHAM PARK,…
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
June 06, 2025 16:05 ET | Source: PolyPid Ltd. PETACH TIKVA, Israel, June…